<DOC>
	<DOC>NCT01358578</DOC>
	<brief_summary>This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.</brief_summary>
	<brief_title>Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Subjects with chronic, plaquetype psoriasis for at least 6 months Must have moderate to severe psoriasis based on PASI greater than 12, IGA greater than 3, and greater than 10% body surface area Must be inadequately controlled by prior treatments (topicals, phototherapy, and/or systemic therapies) Forms of psoriasis other than chronic, plaquetype (such as pustular, erythrodermic and guttate psoriasis) Drug induced psoriasis Use of other psoriasis treatments during the study Prior use of etanercept Prior use of secukinumab or any other drug that target IL17 (interleukin 17) or the IL17 receptor Pregnant or lactating women; women who do not agree to use contraception during the study and for 16 weeks after stopping treatment Significant medical problems such as uncontrolled high blood pressure, congestive heart failure, etc. History of an ongoing, chronic or recurrent infection or evidence of tuberculosis Allergy to rubber or latex Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Psoriasis,</keyword>
	<keyword>inflammatory skin disease,</keyword>
	<keyword>scaly patches</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>inflammatory skin disease</keyword>
</DOC>